VRM
MRNS

Vectors Research Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Vectors Research Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$10K – 511
2022
Q2 		$10K Buy
+2,000
New +$12.2K ﹤0.01% 368
2022
Q1 		– Sell
-2,000
Closed -$24K – 591
2021
Q4 		$24K Hold
2,000
– – 0.01% 324
2021
Q3 		$23K Hold
2,000
– – 0.01% 300
2021
Q2 		$36K Buy
+2,000
New +$32.2K 0.01% 263

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Vectors Research Management's MRNS Position: Q3 2022 in Review

Vectors Research Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 2,000 shares — an estimated $10K sold.

Vectors Research Management first reported a position in MRNS in Q2 2021 and held it in 4 quarters. The position peaked at $36K in Q2 2021. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Vectors Research Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 2,000 Marinus Pharmaceuticals, Inc shares in Q3 2022, an estimated $10K.
  • Vectors Research Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2021 and held it in 4 quarters.
  • Vectors Research Management's Marinus Pharmaceuticals, Inc position peaked at $36K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.